EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, SkinBioTherapeutics's enterprise value is £17.60 Mil.
SkinBioTherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £0.16 Mil. Therefore, SkinBioTherapeutics's EV-to-Revenue for today is 108.61.
The historical rank and industry rank for SkinBioTherapeutics's EV-to-Revenue or its related term are showing as below:
LSE:SBTX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 91.9 Med: 181.12 Max: 340.22
Current: 108.61
During the past 8 years, the highest EV-to-Revenue of SkinBioTherapeutics was 340.22. The lowest was 91.90. And the median was 181.12.
LSE:SBTX's EV-to-Revenue is ranked worse than 84.47% of 1043
companies
in the Biotechnology industry
Industry Median: 8.21
vs LSE:SBTX: 108.61
The historical data trend for SkinBioTherapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SkinBioTherapeutics's EV-to-Revenue
For the Biotechnology subindustry, SkinBioTherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SkinBioTherapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SkinBioTherapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where SkinBioTherapeutics's EV-to-Revenue falls into.
SkinBioTherapeutics's current Enterprise Value is £17.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SkinBioTherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SkinBioTherapeutics's share price for today is £0.1015.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SkinBioTherapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of SkinBioTherapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
SkinBioTherapeutics (LSE:SBTX) Business Description
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:SBTX has been successfully added to your 